These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 15644992

  • 21. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
    Armitage R, Yonkers K, Cole D, Rush AJ.
    J Clin Psychopharmacol; 1997 Jun; 17(3):161-8. PubMed ID: 9169959
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR.
    J Clin Psychiatry; 1996 Jun; 57 Suppl 2():15-8. PubMed ID: 8626358
    [Abstract] [Full Text] [Related]

  • 31. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
    Sajatovic M, DiGiovanni S, Fuller M, Belton J, DeVega E, Marqua S, Liebling D.
    Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
    [Abstract] [Full Text] [Related]

  • 32. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination.
    Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, Thase ME.
    J Clin Psychiatry; 2009 Mar; 70(3):354-61. PubMed ID: 19192474
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.
    Sánchez-Lacay JA, Lewis-Fernández R, Goetz D, Blanco C, Salmán E, Davies S, Liebowitz M.
    Depress Anxiety; 2001 Mar; 13(3):118-24. PubMed ID: 11387731
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
    Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY, Macher JP.
    Psychopharmacol Bull; 1996 Mar; 32(4):637-46. PubMed ID: 8993085
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.